Tolerance to daytime sedative effects of H1 antihistamines.
about
Mechanism of Sleep Disturbance in Children with Atopic Dermatitis and the Role of the Circadian Rhythm and MelatoninRepeated-dose effects of mequitazine, cetirizine and dexchlorpheniramine on driving and psychomotor performanceMisuse and dependence on non-prescription codeine analgesics or sedative H1 antihistamines by adults: a cross-sectional investigation in FranceH1-antihistamine up-dosing in chronic spontaneous urticaria: patients' perspective of effectiveness and side effects--a retrospective survey studyGenetic Analysis of Histamine Signaling in Larval Zebrafish Sleep.Good night and good luck: norepinephrine in sleep pharmacologyAdvances in the management of insomniaAcute and subchronic effects of bilastine (20 and 40 mg) and hydroxyzine (50 mg) on actual driving performance in healthy volunteers.A psychopharmacological treatment algorithm for generalised anxiety disorder (GAD)Differential effects of acute and repeat dosing with the H3 antagonist GSK189254 on the sleep-wake cycle and narcoleptic episodes in Ox-/- mice.The evolution and development of insomnia pharmacotherapiesPharmacological Treatment of Insomnia.Therapeutic options for sleep-maintenance and sleep-onset insomnia.Mirtazapine provokes periodic leg movements during sleep in young healthy men.New approaches in the treatment of short term and middle of the night insomnia: emerging evidence for a role for sublingual zolpidem tabletsCritical appraisal of bilastine for the treatment of allergic rhinoconjunctivitis and urticariaThe effectiveness of acupuncture on the sleep quality of elderly with dementia: a within-subjects trial.Indiplon in the treatment of sleep disorders.Optimizing the Pharmacologic Treatment of Insomnia: Current Status and Future HorizonsSelective histamine H1 antagonism: novel hypnotic and pharmacologic actions challenge classical notions of antihistamines.From pharmacokinetics to therapeutics.Effectiveness and safety of antihistamines up to fourfold or higher in treatment of chronic spontaneous urticariaSafety and efficacy of bilastine: a new H(1)-antihistamine for the treatment of allergic rhinoconjunctivitis and urticaria.Pharmacotherapy of insomnia.New and emerging pharmacotherapeutic approaches for insomnia.New Developments in Insomnia Medications of Relevance to Mental Health Disorders.Diphenhydramine as a selective probe to study H+-antiporter function at the blood-brain barrier: Application to [11C]diphenhydramine positron emission tomography imaging.Low doses of mirtazapine or quetiapine for transient insomnia: A randomised, double-blind, cross-over, placebo-controlled trial.A case of dose escalation of quetiapine in persistent insomnia disorder.Chronic dosing with mirtazapine does not produce sedation in rats.Effects of repeated dosing with mirtazapine, trazodone, or placebo on driving performance and cognitive function in healthy volunteers.How do pharmacists respond to complaints of acute insomnia? A simulated patient study.Pharmacotherapy of Insomnia.Low-dose doxepin (3 and 6 mg) for the treatment of insomnia
P2860
Q26752630-3E441B76-A7E4-4F89-859F-EC2776DC9D19Q28289605-DC072563-CFD0-4B88-B254-E57F19C52ABFQ28534016-B236F4C4-58C4-41CA-A624-A63CB9274054Q28740885-A5EEF814-316F-4E4C-9134-D2B108F92959Q30361534-B65AE9C8-3ACA-46BC-B33E-F4D904A7AD30Q33615826-79452BE8-0E03-4EE1-8CBE-B453980F13A2Q33720437-F53097B8-AB7B-4997-BC46-529785ECB026Q34139004-88AB5195-E62E-497E-BD96-DA526A2B61BEQ34183517-8B1DA960-7105-4B6F-9A98-50E3FAADA87CQ34979043-9FC5256D-5B65-48BB-8B64-A778001B6237Q35995365-A032BD4A-2C1C-4E2A-ADB5-D01C8C4EBA8CQ36251904-051136D2-893E-46A1-9662-2140238B80B8Q36693857-A18D398A-FD8E-45EE-9711-262675C77DAEQ36761266-C5C3E200-4FEB-4D16-B194-54F94FFB285EQ36779781-15848DDC-ACBD-4142-BA46-DF4ABB32C864Q36833151-14DA2611-F9CC-4789-91ED-24313E7A31EBQ37079097-CBFEC01F-9C00-407E-B905-DCC9059CC685Q37129808-25D41E9B-5629-46E7-8E5B-E6391AACF9FEQ37149325-44001793-50E4-4C21-BE9A-1125A6457659Q37380606-194C8FC2-C182-4712-9D59-E36E68CAF7E9Q37550564-47A16647-DCA0-4710-BB29-33BF6529F4F6Q37642908-00D5275A-8FE1-4E45-90E2-6020ACC483D2Q37914886-B18DDB29-0199-4BB1-B760-2209DA005E86Q38009370-B63BFDE8-BD3C-4399-B963-B6078AE5B7E2Q38217284-D1FDA000-D637-4A38-9EA8-58249B614621Q38645553-046C3FF2-D2FB-44FA-BFA1-073DA16C742EQ47402029-20C108C8-9251-4DA0-8425-68EA61EC10D5Q47774281-6292A611-90A0-4FD7-8FC8-E3D4BCF83F6DQ47784627-A14393BA-A4B5-4C8F-8CD4-BD4B99BE82F1Q47931148-F8A8A02E-C356-4032-9E0C-2DF149551F88Q48178559-A5509104-B180-4BA9-B441-3889D04AE8D6Q48312828-6B890412-4D3C-476F-A10A-2447031CA96DQ55463269-1B427AE2-9563-4D9C-939E-35164734D74AQ57487833-38CE1E24-3CF5-4677-8D74-42F7750CC0D9
P2860
Tolerance to daytime sedative effects of H1 antihistamines.
description
2002 nî lūn-bûn
@nan
2002 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Tolerance to daytime sedative effects of H1 antihistamines.
@ast
Tolerance to daytime sedative effects of H1 antihistamines.
@en
Tolerance to daytime sedative effects of H1 antihistamines.
@nl
type
label
Tolerance to daytime sedative effects of H1 antihistamines.
@ast
Tolerance to daytime sedative effects of H1 antihistamines.
@en
Tolerance to daytime sedative effects of H1 antihistamines.
@nl
prefLabel
Tolerance to daytime sedative effects of H1 antihistamines.
@ast
Tolerance to daytime sedative effects of H1 antihistamines.
@en
Tolerance to daytime sedative effects of H1 antihistamines.
@nl
P2093
P1476
Tolerance to daytime sedative effects of H1 antihistamines.
@en
P2093
Gail Koshorek
Gary S Richardson
Leon Rosenthal
Thomas Roth
Timothy A Roehrs
P304
P356
10.1097/00004714-200210000-00012
P407
P577
2002-10-01T00:00:00Z